|
|
|
|
|
|
|
|
|
02.07.26 - 16:42
|
Ipsen übernimmt die Memo Therapeutics AG (Moneycab)
|
|
|
Die Aktionäre der Memo Therapeutics AG erhalten bei Abschluss der Transaktion eine Zahlung in Höhe von 200 Millionen Euro auf bargeld- und schuldenfreier Basis, bei einer potenziellen Gesamtgegenleistung von über 700 Millionen Euro....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
01.07.26 - 07:03
|
Ipsen to acquire Memo Therapeutics AG, adding first-in-class BK polyomavirus antibody, expanding rare disease portfolio (GlobeNewswire EN)
|
|
|
PARIS, FRANCE AND SCHLIEREN/ZURICH, SWITZERLAND, 01 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Memo Therapeutics AG announced today they have entered into a definitive share purchase agreement under which Ipsen has agreed to acquire all issued and outstanding shares of Memo Therapeutics AG. The anticipated acquisition is focused on potravitug, which is a Phase II clinical-stage antibody against the BK polyomavirus (BKPyV). BK polyomavirus associated nephropathy (BKPyVAN) is a serious and frequent clinical complication in renal transplanted patients that can lead to graft loss and transplant failure. Potravitug was granted fast-track designation from the U.S. Food and Drug Administration (FDA) in May 2023 and orphan drug designation in the European Union in December 2025....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
29.06.26 - 07:03
|
Ipsen to acquire Kartos Therapeutics, expanding hemato-oncology late-stage pipeline (GlobeNewswire EN)
|
|
|
PARIS, FRANCE AND REDWOOD CITY, U.S., 29 JUNE 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) and Kartos Therapeutics, announced today they have entered into a definitive merger agreement under which Ipsen has agreed to acquire Kartos Therapeutics. The acquisition adds navtemadlin, an investigational MDM2 inhibitor designed to restore the natural tumor-suppressing function of p53, a critical tumor-suppressor in myelofibrosis. Data show strong therapeutic potential of navtemadlin for intermediate and high-risk TP53 wild-type (wt) myelofibrosis as an add-on treatment for patients with a suboptimal response to standard of care ruxolitinib....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
